The current work examined the potential of employing ARV-825 and ABBV-744 to enhance the effectiveness of tamoxifen or fulvestrant as well as palbociclib. ARV-825 was effective in both of those p53 wild-type (WT) breast tumor cells As well as in cells missing useful p53 either by itself or in combination https://abbv-744-for-small-cell-l02356.verybigblog.com/31484452/5-essential-elements-for-abbv-744-drug-development-progress-and-timeline